CONy 2021 | Searching for therapeutic targets for Parkinson’s disease

Gennaro Pagano, MD, MSc, PhD, F. Hoffmann-La Roche Ltd, Basel, Switzerland, King’s College London, London, UK, comments on treatment approaches for Parkinson’s disease. Parkinson’s disease is a complex disease that develops over many years, from the first prodromal symptoms to the classic motor symptoms of this neurodegenerative disease. Targeting aggregated alpha-synuclein (α-syn) is a promising approach slow down disease progression, especially in combination with drugs targeting other pathways involved in Parkinson’s disease pathogenesis. This interview was conducted during the virtual 2021 World Congress on Controversies in Neurology (CONy).